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1. INTRODUCTION	  	  
Neonatal	   seizures	   are	   the	   most	   frequent	   clinical	   manifestation	   of	   central	   nervous	   system	  
dysfunction	   in	   the	   newborn,	   with	   an	   incidence	   of	   1.5-­‐3.5/1000	   in	   term	   newborns	   and	   10-­‐
130/1000	  in	  preterm	  newborns	  (1).	  Furthermore	  they	  are	  a	  major	  risk	  for	  death	  or	  subsequent	  
neurological	  disability	  and	  can	  independently	  confer	  an	  adverse	  neurodevelopmental	  outcome	  
in	  high-­‐risk	  neonates	  (2).	  
Physiopathology	  	  
A	  seizure	  is	  a	  sudden,	  excessive,	  synchronous	  electrical	  discharge	  of	  a	  group	  of	  neurons	  within	  
the	   central	   nervous	   system.	   This	   electrical	   discharge	   is	   due	   to	   depolarization	   of	   neurons,	  
resulting	  from	  an	  influx	  of	  sodium	  ions.	  Negative	  potential	  across	  neuronal	  cells	  is	  maintained	  
by	  an	  ATP	  (adenosine	  triphosphate)	  dependant	  Na+	  -­‐	  K+	  pump.	  Depolarization	  can	  result	  from	  
one	  of	  four	  mechanisms:	  	  
1) Decreased	  energy	  production	  and	  failure	  of	  ATP	  dependant	  Na+	  -­‐	  K+	  pump	  	  
2) Excessive	   release	   of	   the	   excitatory	   neurotransmitter	   glutamate	   and	   reduced	   (energy	  
dependant)	  uptake	  into	  cells.	  
3) Deficiency	   of	   inhibitory	   neurotransmitters:	   gamma-­‐amino	   butyric	   acid	   (GABA)	   is	   the	  
predominant	   inhibitory	   neurotransmitter	   in	   the	   brain.	   A	   deficiency	   of	   pyridoxine,	   a	  
cofactor	  for	  GABA	  synthesis,	  will	   lead	  to	  reduced	  levels	  of	  GABA	  and	  consequently	  to	  
seizures.	  
4) Hypocalcaemia	   and	   hypomagnesaemia	   also	   cause	   seizures	   as	   both	   calcium	   and	  
magnesium	  inhibit	  Na+	  movement	  across	  neuronal	  cells.	  	  
PURPOSE:	   To	   analyze	   if	   the	   use	   of	   Phenobarbital	   compared	   with	   Levetiracetam,	   it’s	  
associated	   with	   more	   neurodevelopmental	   problems	   in	   newborns	   treated	   for	   neonatal	  
seizures.	   As	   a	   secondary	   objective	   identify	   which	   are	   the	   most	   affected	   areas	   of	   the	  
neurodevelopment:	  cognition,	  socio-­‐emotional,	  motor	  or	  language	  skills.	  	  
DESIGN:	   A	   5	   years	   long	   clinical	   trial	   administering,	   with	   double-­‐blind	   and	   a	   randomized	  
distribution	  of	  the	  sample,	  Phenobarbital	  or	  Levetiracetam	  for	  the	  management	  of	  neonatal	  
seizures	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Then	   as	   it’s	   seen,	   glutamate	   is	   the	  major	   excitatory	  neurotransmitter	   in	   the	   central	   nervous	  
and	  GABA	  the	  major	   inhibitory	   transmitter.	  Glutamate	   receptors	  are	   located	  at	   synapses,	  on	  
non-­‐synaptic	  sites,	  on	  neurons	  and	  on	  glia,	  and	  it	  has	  3	  types	  of	  receptors:	  NMDA	  receptor	  (N-­‐
methyl-­‐D-­‐aspartate),	   AMPA	   receptor	   (alpha-­‐amino-­‐3	   hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	  
acid)	   and	   kainitine	   receptor.	   However	   the	   neonatal	   central	   nervous	   system	   has	   some	  
differences	  related	  to	  glutamate	  and	  GABA	  functions.	   In	  the	  neonatal	  brain,	  both	  NMDA	  and	  
AMPA	  receptors	  are	  over	  expressed	  and	  their	  subunit	  composition	  renders	   them	  susceptible	  
to	   enhanced	   excitability.	   Moreover	   to	   compound	   the	   relative	   excess	   of	   ‘excitability’	   of	   the	  
perinatal	   brain,	   GABA	   receptor	   expression	   is	   low	   in	   early	   life.	   In	   addition,	   GABA	   receptor	  
activation	   produces	   excitation	   rather	   than	   inhibition	   of	   neurotransmission.	   This	   paradoxical	  
action	   of	   GABA	   in	   the	   neonate	   is	   due	   to	   age	   related	   differences	   in	   chloride	   homeostasis.	  
Chloride	   transport	   is	   a	   function	   of	   two	   membrane	   pumps.	   In	   the	   neonate	   Na+-­‐K+-­‐Cl-­‐	   co-­‐
transporter	  (NKCC1)	  imports	  large	  amounts	  of	  chloride	  into	  the	  neuron.	  Chloride	  levels	  within	  
the	  neuron	  remain	  high	  because	  of	   relative	  under	  expression	  of	  K+-­‐Cl-­‐	   co-­‐transporter,	   (KCC2)	  
which	   is	  a	  K+	  exporter.	  When	  the	  chloride	  permeable	  GABA	  receptors	  are	  activated,	  chloride	  
flows	   out	   of	   the	   cell	   depolarizing	   it.	   As	   a	   result	   GABA	   activation	   is	   excitatory	   rather	   than	  
inhibitory.	   With	   maturation,	   NKCC1	   expression	   diminishes	   and	   KCC2	   expression	   increases.	  
GABA	  activation	  then	  causes	  chloride	  to	  flow	  into	  the	  cell	  and	  hyperpolarize	  it.	  Maturation	  of	  
these	  chloride	  co-­‐transporters	  occurs	  in	  a	  caudal	  to	  rostral	  direction	  with	  maturation	  of	  spinal	  
cord	  and	  brain	  stem	  receptors	  occurring	  before	  that	  of	  the	  cerebral	  cortex	  (3).	  	  
Aetiology	  of	  neonatal	  seizures	  
	  
Hypoxic-­‐ischemic	   encephalopathy	   (HIE),	   intracranial	   haemorrhage,	   intracranial	   infection	   and	  
developmental	  defects	  are	  responsible	  for	  80-­‐85%	  of	  all	  causes	  of	  neonatal	  seizures	  (1).	  	  
	  
Hypoxic-­‐ischemic	  encephalopathy	   remains	   the	  most	   frequent	  underlying	  cause	  of	   seizures	   in	  
term	   infants	   (1,4,5).	   It	   contributes	   to	   40-­‐60%	   of	   seizures	   in	   term	   infants	   (1).	   This	   seizures	  
occurring	  in	  infants	  with	  HIE	  may	  contribute	  to	  a	  poor	  neurodevelopmental	  outcome	  (6,7),	  and	  
they	  predominantly	  occur	  within	  the	  first	  24h	  (1,4,5).	  	  
Cerebrovascular	   disorders	   are	   the	   second	  most	   frequent	   cause	   of	   neonatal	   seizures	   (1,4,5).	  
Within	   this	   group	   we	   can	   find	   intraventricular	   haemorrhage:	   grade	   3	   or	   4	   are	   the	   most	  
significant	   cause	   of	   seizures	   in	   preterm	   in	   the	   first	   3	   days	   of	   life	   (1),	   large	   subarachnoid	  
haemorrhage	  can	  occasionally	  lead	  to	  seizures	  that	  tend	  to	  occur	  on	  the	  second	  day	  of	  life	  (1),	  
and	  large	  subdural	  haemorrhages	  which	  are	  associated	  with	  traumatic	  delivery	  (8).	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Central	  nervous	  system	  infections	  are	  present	  in	  about	  5-­‐10%	  of	  babies	  with	  neonatal	  seizures	  
(1),	  and	  commonly	  take	  the	  form	  of	  meningitis,	  but	  viral	  meningoencephalitis	  particularly	  due	  
to	  herpes	  simplex	  virus	  is	  also	  a	  well-­‐recognised	  cause	  (8).	  	  
Cortical	   malformations	   account	   for	   5-­‐9%	   of	   all	   causes	   of	   neonatal	   seizures	   (5).	   The	   more	  
widespread	   malformations	   include	   tuberous	   sclerosis,	   focal	   cortical	   dysplasia,	  
hemimegalencephaly,	   lissencephaly,	   subcortical	   band	   heterotopia,	   periventricular	   nodular	  
heterotopia,	  schizencephaly	  and	  plimicrogyira	  (8).	  	  
	  
The	   15-­‐20%	   that	   rest	   are	   caused	   by	   transistent	   metabolic	   causes	   as	   hypoglycaemia,	  
hypocalcemia/hypomagnesemia,	   hypernatraemia/hyponatremia,	   or	   innborn	   errors	   of	  
metabolism	  (8).	  
Types	  and	  diagnosis	  of	  seizures	  
	  
Four	  main	  types	  of	  seizures	  are	  recognised	  (9):	  
• Subtle:	  include	  oro-­‐facial	  manifestations	  such	  as	  eye	  deviation,	  eyelid	  blinking,	  sucking,	  
chewing	  and	  lip	  smacking.	  Limb	  movements	  described	  as	  swimming,	  boxing	  or	  cycling	  
can	   also	   indicate	   subtle	   seizure	   activity.	   Apnoeic	   episodes	   can	   be	   due	   to	   seizures.	  
There	   can	   be	   difficulty	   distinguishing	   subtle	   seizures	   from	   jittering,	   an	   extremely	  
common	   normal	   phenomenon	   in	   newborns.	   Jittering	   does	   not	   involve	   the	   face,	   is	  
markedly	  stimulus	  sensitive,	  and	  ceases	  when	  the	  limb	  is	  held.	  The	  autonomic	  nervous	  
system	  changes	  of	   a	   seizure,	   such	  as	   tachycardia	  or	  hypertension,	   are	  never	   seen	   in	  
jittering	  (9).	  	  
• Clonic:	   involve	   one	   limb	   or	   one	   side	   of	   the	   face	   or	   body	   jerking	   rhythmically	   at	   a	  
frequency	  of	  1–4	  times/s.	  Clonic	  seizures	  in	  the	  neonate	  can	  have	  more	  than	  one	  focus	  
or	  migrate.	  They	  are	  often	  a	  clue	  to	  an	  underlying	  focal	  lesion	  but	  they	  can	  be	  due	  to	  a	  
metabolic	  cause.	  Infants	  are	  not	  usually	  unconscious	  during	  this	  kind	  of	  seizures	  (9).	  	  
• Tonic:	  Sustained	  posturing	  of	  the	  limbs	  or	  trunk,	  or	  deviation	  of	  the	  head	  or	  eyes	  are	  
the	  usual	  manifestations	  (9).	  
• Myoclonic:	  tend	  to	  occur	  in	  the	  flexor	  muscle	  groups	  (9).	  	  
	  
For	  a	  correct	  diagnosis	  we’ll	  have	  to	  perform	  the	  following	  steps:	  
	  
• Detailed	   clinical	   examination:	   we	   have	   to	   perform	   it	   in	   all	   infants	   with	   suspected	  
seizures.	   The	   neurological	   examination	   should	   include	   an	   assessment	   of	   the	   level	   of	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consciousness,	  tone,	  gaze,	  body-­‐posture,	  tendon,	  cranial	  nerve	  and	  newborn	  reflexes.	  
The	   general	   body	   examination	   focuses	   on	   finding	   indications	   for	   an	   underlying	  
disease/condition.	   The	   skin	   is	   inspected	   for	   bleeding	   and	   bruising,	   eruptions,	   birth-­‐
marks	  (for	  example	  in	  the	  face,	  indicating	  phacomatosis).	  Cardiac	  examination	  includes	  
checking	  for	  murmurs,	  including	  auscultation	  over	  the	  fontanelle	  as	  AV	  malformations	  
can	   be	   diagnosed	   this	   way.	   Abdominal	   examination	   focuses	   on	   intra-­‐	   abdominal	  
masses	  (liver,	  spleen,	  kidneys)(10).	  	  
• Initial	  laboratory	  work-­‐up:	  this	  one	  will	  be	  focused	  on	  finding	  those	  conditions	  where	  
an	   immediate	   treatment	   is	   mandatory	   either	   to	   save	   the	   life	   of	   the	   infant,	   or	   to	  
minimize	   the	   ongoing	   brain	   damage	   and	   thereby	   reduce	   any	   subsequent	  
neurodisability	   in	   surviving	   children.	   It	   is	   important	   to	   prioritize	   laboratory	   tests	  
directed	   at	   the	   recognition	   of	   metabolic	   disturbances	   and	   infections	   that,	   if	   un-­‐
treated,	   can	   lead	   to	   permanent	   brain	   damage.	   Hypoglycaemia	   is	   readily	   identified	  
using	   point-­‐of-­‐care	   techniques,	   and	   the	   rapid	   start	   of	   i.v.	   glucose	   can	   be	   rapidly	  
achieved.	   In	   addition,	   serum	   concentrations	   of	   sodium,	   potassium,	   calcium	   and	  
magnesium	   should	   be	   analysed.	   Blood-­‐gas	   analysis	   will	   indicate	   whether	   there	   is	   a	  
lactic	   acidosis	   that	   would	   warrant	   further	   metabolic	   screening.	   	   If	   initial	   laboratory	  
testing	  is	  negative	  a	  more	  thorough	  investigation	  should	  take	  place	  aiming	  to	  rule	  out	  
rare	  causes	  of	  neonatal	  seizures	  (10).	  
• Neurophysiologic	  diagnosis	  and	  monitoring:	  Seizures	  in	  the	  newborn	  are	  notoriously	  
difficult	   to	  diagnose	  as	   clinical	   signs	  may	  be	   very	   subtle	  or	   completely	   absent	   (1).	   In	  
addition,	   there	   is	   a	   considerable	   mismatch	   between	   clinical	   and	   electrographic	  
diagnosis	  of	  neonatal	  seizure	  (11).	  Neonates	  can	  make	  jerky	  movements	  that	  may	  be	  
misinterpreted	   as	   seizures	   and	  may	   receive	  multiple	   antiepileptic	   drugs	   (AEDs)	   over	  
many	  days,	   become	   sedated,	   cannot	  breast	   feed	   and	   remain	   in	  hospital	   longer	   than	  
necessary	  because	  of	  this	  imprecision	  in	  diagnosis.	  Other	  babies	  are	  under	  treated	  and	  
spend	  hours	  in	  status	  epilepticus.	  EEG	  monitoring	  is	  the	  only	  reliable	  method	  available	  
for	  the	  detection	  of	  neonatal	  seizures	  (12).	  In	  view	  of	  this	  diagnostic	  complexity,	  some	  
argue	  that	  diagnosis	  of	  neonatal	  seizures	  should	  not	  be	  based	  on	  clinical	  observation	  
alone.	   As	   EEGs	   are	   difficult	   to	   obtain	   round	   the	   clock	   on	   the	   neonatal	   unit,	   initial	  
diagnosis	  and	  treatment	  is	  based	  on	  clinical	  observation.	  Several	  centres	  are	  now	  using	  
amplitude	  integrated	  EEG	  (aEEG)	  as	  a	  readily	  available	  bedside	  tool.	  This	  device	  uses	  a	  
single	  or	  dual	   channel	   EEG	  and	  acute	   variations	   in	   spectral	  width	   to	  detect	   seizures.	  
Several	   reports	   show	   that	   aEEG	   detects	   approximately	   75%	   of	   seizures	   detected	   by	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conventional	  EEGs	  (3).	  
• Neuroimaging:	  Cranial	  ultrasound	  is	  readily	  available	  in	  most	  modern	  NICUs	  and	  offers	  
a	   rapid	   cotside	   tool	   with	   the	   possibility	   of	   identifying	  many	   intracranial	   pathologies	  
(13,14).	  A	   cranial	  ultrasound	   is	   routine	  management	   in	   the	   investigation	  of	  neonatal	  
seizures.	   It	   should	   be	   carried	   out	   as	   soon	   as	   possible	   after	   the	   first	   occurrence	   of	  
seizures	   and	   will	   help	   in	   early	   diagnosis	   of	   many	   underlying	   causes	   including	  
intraventricular	  haemorrhage,	   arterial	   stroke,	  malformation	  and	   infections.	  Magnetic	  
resonance	   imaging	   (MRI)	   is	   the	   ‘gold	   standard’	   in	   the	   examination	   of	   the	   newborn	  
brain	  and	  will	  reveal	  most	  brain	  pathology	  (14,15).	  	  	  	  
Treatment	  
	  
Although	  immature	  brain	  is	  more	  prone	  to	  seizures,	  it	  is	  more	  resistant	  to	  post	  seizure	  damage	  
than	  the	  mature	  brain.	  However,	  evidence	  from	  several	  animal	  models	  and	  a	   few	  studies	  on	  
human	   infants	   have	   shown	   that	   prolonged	   and	   recurrent	   seizures	   have	  widespread	   effects,	  
which	   are	   deleterious	   to	   the	   developing	   brain.	   Specifically,	   animal	   studies	   have	   shown	   that	  
seizures	   result	   in	   reduced	   density	   of	   dendritic	   spines	   in	   hippocampal	   pyramidal	   neurons,	  
delayed	   neuronal	   loss,	   decreased	   neurogenesis,	   synaptic	   reorganization	   and	   changes	   in	  
hippocampal	  plasticity	  (3),	  and	  although	  the	  prognosis	  of	  neonatal	  seizures	  has	  improved	  over	  
the	   past	   several	   decades,	   approximately	   one	   third	   of	   survivors	   are	   still	   left	   with	   neurologic	  
sequelae	  including	  motor	  deficits,	  mental	  handicap,	  and	  epilepsy	  (1).	  	  
According	   to	   this	   data	   and	   the	   difficulty	   to	   diagnose	   a	   seizure	   episode	  many	   neonatologists	  
have	  decided	  to	  treat	  seizures	  by	  the	  “rule	  of	  3”:	  more	  than	  three	  seizures	  per	  hour	  or	  if	  any	  
one	  seizure	  lasts	  more	  than	  3	  minutes	  (3)	  and	  even	  thought	  a	  2004	  Cochrane	  report	  concluded	  
that	   there	  was	   little	   evidence	   to	   support	   the	   use	   of	   any	  Antiepilpetic	  Drug	   (AED),	   these	   are	  
currently	  used	  in	  the	  neonatal	  period	  to	  treat	  seizures	  (16).	  	  
First-­‐generation	   AEDs,	   such	   as	   phenobarbital	   and	   phenytoin,	   are	   the	   drugs	   of	   first	   (and	  
second/third)	   choice	   because	   of	   extensive	   clinical	   experience	   (17).	   Phenobarbital	   is	   a	   GABA	  
agonist	  and	  it	  controls	  70%	  of	  clinical	  seizures	  and	  50%	  of	  electrical	  seizures,	  it	  has	  a	  long	  half-­‐
life	   (2-­‐4	  days)	  and	  enters	  CSF	   rapidly.	  The	   loading	  dose	   is	  20mg/kg	  and	  achieves	   therapeutic	  
levels	  (20-­‐40mg/litre)	  in	  the	  serum	  within	  a	  short	  time.	  And	  phenytoin	  acts	  reducing	  electrical	  
conductance	  in	  neurons	  by	  stabilizing	  sodium	  channels,	  having	  as	  side	  effects	  hypotension	  and	  
arrhythmias	  that	  reach	  to	  a	  constant	  cardiac	  monitoring	  (3).	  However	  they	  have	  limited	  clinical	  
effectiveness	  and	  potential	  neurotoxicity	  (17).	  Several	  studies	  support	  this	  idea	  and	  have	  been	  
used	  as	  a	  reference	  for	  further	  investigations	  about	  the	  neurotoxicity	  of	  antiepileptic	  drugs.	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A	   study	   performed	   in	   2002	   by	   P.	   Bittigau	   revealed	   that	   phenobarbital,	   phenitoyn	   and	   other	  
antiepileptic	   drugs	   as	   diazepam,	   clonazepam,	   vigabatrin,	   and	   valproate	   cause	   apoptotic	  
neurodegeneration	   in	   the	  developing	   rat	  brain	  at	  plasma	  concentrations	   relevant	   for	   seizure	  
control	  in	  humans.	  To	  determine	  whether	  AEDs	  exert	  neurotoxic	  effects	  in	  the	  developing	  rat	  
brain,	   they	   injected	   rats	   i.p.	   with	   phenytoin,	   phenobarbital,	   pentobarbital,	   diazepam,	  
clonazepam,	   vigabatrin,	   or	   valproate	  on	  postnatal	   day	   7	   (P7)	   and	   analyzed	   their	   brains	   24	  h	  
later.	   Phenytoin	   (10–50mg/kg)	   produced	   widespread	   neurodegeneration	   on	   P7	   and	   the	  
neurotoxic	   action	   in	   the	   forebrain	   was	   dose-­‐dependent.	   Phenobarbital	   (20–100	  mg/kg)	   and	  
diazepam	  (5–30	  mg/kg)	  caused	  widespread	  apoptotic	  neurodegeneration	  in	  the	  brains	  of	  rats	  
on	  P7.	  Neurotoxic	  effects	  were	  reproduced	  by	  pentobarbital	  (5	  or	  10	  mg/kg)	  and	  clonazepam	  
(0.5–4mg/kg)	  in	  7-­‐day-­‐old	  rats	  and	  the	  threshold	  doses	  for	  triggering	  apoptotic	  brain	  damage	  
were	  40mg/kg	  for	  phenobarbital,	  10mg/kg	  for	  diazepam,	  and	  0.5mg/kg	  for	  clonazepam.	  Finally	  
valproate	   (50–400	   mg/kg	   on	   P7)	   or	   vigabatrin	   (50,	   100,	   or	   200	   mg/kg	   twice	   daily	   on	   3	  
consecutive	   days	   starting	   on	   P5)	   elicited	   apoptotic	   neurodegeneration	   in	   the	   developing	   rat	  
brain	   in	   a	   dose-­‐dependent	   manner.	   The	   threshold	   dose	   for	   valproate	   was	   50	   mg/kg	   and	  
resulted	  in	  a	  peak	  valproate	  plasma	  concentration	  of	  80	  μg/ml,	  which	  rapidly	  declined	  within	  8	  
h	   and	  100	  mg/kg	   for	   vigabatrin	   given	   twice	  daily	   on	  3	   consecutive	  days.	   They	   reported	   that	  
major	   AEDs	   cause	   sensitive	   neurons	   to	   undergo	   apoptotic	   death	   in	   the	   developing	   rat	  
forebrain	  and	   for	  phenobarbital,	   they	   found	   that	  plasma	   concentrations	  between	  25	  and	  35	  	  
μg/ml	   over	   a	   12-­‐h	   period	   triggered	   apoptotic	   neurodegeneration	   in	   infant	   rats	   (17),	   a	  
concentration	   easily	   achieved	   when	   phenobarbital	   was	   given	   to	   human	   infants	   (3).	   This	   is	  
crucial	  during	  the	  period	  when	  the	  proapoptotic	  effect	  of	  AEDs	  coincides	  with	  the	  brain	  growth	  
spurt	  that	  is,	  for	  humans,	  the	  third	  trimester	  of	  gestation	  until	  several	  years	  after	  birth	  (17).	  	  
In	  2010	  a	   second	  study	  performed	  by	  P.	  A.	  Forcelli	  PhD	  and	  based	  on	  Bittigau’s	  conclusions,	  
compared	  the	  effects	  of	  acute	  (on	  P7	  or	  P14)	  or	  chronic	  (daily	  treatment	  from	  P7	  to	  P14)	  use	  
of	  phenobarbital	  during	  the	  period	  between	  P7	  and	  P14.	  They	  presented	  preliminary	  findings	  
on	   striatal	   synaptic	   function,	  development	  of	   reflexes,	   and	   longer-­‐term	  behaviours	   that	  may	  
prove	  useful	  in	  detecting	  functional	  impairment	  associated	  with	  AED-­‐induced	  neurotoxicity.	  As	  
a	   result	   they	   found	   that	   adult	   animals	   that	   had	   been	   exposed	   to	   phenobarbital	   as	   pups	  
between	  P7	  and	  P14	  exhibited	  impaired	  fear	  conditioning,	  impaired	  sensory-­‐motor	  gating,	  and	  
altered	  anxiety-­‐like	  behaviour	  (18).	  	  
Same	  author	  developed	  a	  study	  in	  2012	  to	  examine	  functional	  synaptic	  maturation	  in	  striatal	  
medium	   spiny	   neurons	   from	  neonatal	   rats	   exposed	   to	   antiepileptic	   drugs	  with	   proapoptotic	  
action	   (phenobarbital,	   phenytoin,	   lamotrigine)	   and	   without	   proapoptotic	   action	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(levetiracetam).	   To	   assess	   the	   impact	   of	   phenobarbital	   on	   functional	   synaptic	  maturation	   in	  
infancy,	  they	  employed	  the	  neonatal	  rat	  as	  a	  preclinical	  model.	  In	  pups	  between	  postnatal	  day	  
P10	  and	  P18,	  the	  maturation	  of	  inhibitory	  and	  excitatory	  postsynaptic	  currents	  were	  examined	  
in	  striatum	  (19),	  a	  brain	  region	  that	  displays	  reduced	  volume	  in	  human	  imaging	  studies	  of	  adult	  
patients	   exposed	   to	   AEDs	   early	   in	   life	   (20).	   They	   compared	   the	   effects	   of	   exposure	   to	  
phenobarbital	   to	   the	   effects	   of	   exposure	   to	   3	   other	   AEDs:	   phenytoin,	   lamotrigine,	   and	  
levetiracetam.	  Phenytoin	   is	  currently	  a	  second	   line	   treatment	   for	  neonatal	   seizures,	  whereas	  
lamotrigine	   and	   levetiracetam	   are	   newer	   generation	   AEDs	   that	   are	   believed	   to	   have	   an	  
especially	   favourable	   safety	   profile.	   By	   using	   patch-­‐clamp	   recordings	   and	   morphometric	  
analysis	  of	  striatal	  medium	  spiny	  neurons	  (MSNs),	  they	  examined	  the	  maturation	  of	  GABAergic	  
and	   glutamatergic	   synaptic	   connectivity.	   The	   examination	   of	   the	   maturation	   of	   striatal	  
neuronal	  physiology	  provided	  the	  evidence	  that	  neonatal	  exposure	  to	  AEDs	  delayed	  or	  stunted	  
the	   development	   of	   both	   excitatory	   and	   inhibitory	   synapse	   function.	   This	   results	   where	  
associated	  with	  the	  abnormalities	   in	  motor	  behaviour,	  sensory	  motor	  gating,	  and	  memory	   in	  
adult	  rats	  previously	  described	  by	  the	  same	  author	  (19).	  	  
According	   to	   these	   findings	   and	   results	   the	   scientific	   community	   interested	   in	   this	   field	   has	  
been	  looking	  for	  new	  alternatives,	  new	  AED	  with	  better	  security	  profile	  at	  either	  short	  or	  long	  
term;	  and	  Levetiracetam	  has	  been	  the	  one	  on	  the	  spotlight	  for	  his	  experienced	  good	  security	  
profile	  and	  efficiency.	  Several	  studies	  support	  this	  theory,	  although	  we	  have	  to	  consider	  that	  
they	  all	  had	  small	  samples.	  Ramantani	  et	  al.	  observed	  the	  anticonvulsant	  efficacy	  and	  safety	  of	  
Levetiracetam	  (LEV)	  as	  a	  first-­‐line	  AED	  in	  neonatal	  seizures,	  after	  excluding	  standard	  metabolic	  
causes:	   30/38	   (79%)	   infants	   were	   seizure	   free	   under	   LEV	   at	   the	   end	   of	   the	   first	   week,	   and	  
27/30	   (90%)	   remained	   seizure	   free	   at	   four	   weeks,	   while	   EEGs	   were	   markedly	   improved	   in	  
25/30	   (83%)	   patients	   at	   four	   weeks.	   However	   some	   of	   them	   needed	   and	   adjunctive	  
phenobarbital	   dose	   due	   to	   recurrency.	   Related	   to	   side	   effects	   LEV	   was	   tolerated	   extremely	  
well	   in	   the	   study	   group,	   with	   somnolence	   during	   titration	   (at	   least	   partially)	   attributed	   to	  
adjunctive	   phenobarbital	   therapy	   (21).	   Khan	   et	   al.	   retrospectively	   analyzed	   22	   neonates	  
treated	  with	   intravenous	   levetiracetam.	  Fifteen	  patients	   (68%)	  began	  receiving	   levetiracetam	  
because	  of	  continued	  seizures	  on	  phenobarbital,	  three	  (14%)	  because	  of	  adverse	  reactions	  to	  a	  
previous	   antiepileptic	   drug,	   and	   one	   (5%)	   because	   of	   continued	   seizures	   on	   fosphenytoin.	  
Three	   patients	   (14%)	   were	   initially	   started	   on	   levetiracetam.	   Their	   data	   suggested	   that	  
intravenous	   levetiracetam	  could	  be	  used	   for	   the	  management	  of	  acute	  seizures	   in	  neonates.	  
The	   use	   of	   intravenous	   levetiracetam	  demonstrated	   immediate	   cessation	   of	   seizures	   in	   86%	  
(19/22)	   of	   our	   study	   patients	   and	   concluded	   that	   intravenous	   levetiracetam	   appeared	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efficacious	   in	  the	  management	  of	  acute	  seizures	  during	  the	  neonatal	  period	  and	  again,	   it	  did	  
not	  result	  in	  any	  severe	  adverse	  events	  and	  was	  generally	  well	  tolerated	  (22)	  .	  
	  
According	   to	   all	   this	   there’s	   evidence	   (in	   rat	   studies)	   that	   treatment	  with	   phenobarbital	   for	  
neonatal	  seizures	  could	  be	  related	  to	  poor	  neurodevelopmental	  outcome	  or	  influence	  a	  lowest	  
neurodevelopmental	   outcome.	   If	   we	   keep	   in	   mind	   that	   new	   antiepileptic	   drugs,	   as	  
Levetiracetam,	  are	  proved	  to	  be	  as	  effective	  as	  phenobarbital	  (even	  though	  the	  studies	  had	  a	  
small	  sample)	  and	  that	  Levetiracetam’s	  mechanism	  doesn’t	  cause	  any	  apoptotic	  death	  or	  other	  
damage	   to	   the	   brain;	   supported	   this	   by	   a	   human	   retrospective	   study	   (still	   in	   revision)	   that	  
shows	   that	   there’s	   a	   feasible	   association	   between	   Phenobarbital	   and	   poor	  
neurodevelopmental	   outcome	   compared	  with	   the	   lack	  of	   problems	  with	   the	   treatment	  with	  
Levetiracetam,	  it’s	  encouraging	  us	  to	  develop	  a	  prospective	  study	  and	  a	  long-­‐term	  evaluation	  
of	  neurodevelopmental	  outcome	  in	  order	  to	  establish	  if	  Levetiracetam	  could	  be	  an	  alternative	  
to	   Phenobarbital,	   reducing	   afterwards	   the	   problems	   related	   with	   the	   use	   of	   this	   drug	   and	  
increasing	  the	  life	  quality	  and	  future	  of	  this	  babies.	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3.	  HYPOTHESIS	  	  
Levetiracetam	  has	  best	  neurodevelopmental	  outcome	  than	  Phenobarbital.	  
4.	  OBJECTIVE	  	  
Analyze	  if	  the	  use	  of	  Phenobarbital	  compared	  with	  Levetiracetam,	  it’s	  associated	  with	  more	  
neurodevelopmental	  problems	  in	  newborns	  treated	  for	  neonatal	  seizures.	  
Secondary	  objectives:	  
• Identify	  which	  are	  the	  most	  affected	  areas	  of	  the	  neurodevelopment:	  cognition,	  socio-­‐

























A	  5	  years	   long	  clinical	  trial	  administering,	  with	  double-­‐blind	  and	  a	  randomized	  distribution	  of	  
the	  sample,	  Phenobarbital	  or	  Levetiracetam	  for	  the	  management	  of	  neonatal	  seizures.	  	  
The	  double-­‐blind	  will	  be	  applied	  to	  the	  evaluator	  of	  the	  neurodevelopment	  status	  of	  the	  child,	  
a	  neuropsychologist,	   and	   for	   the	  parents	   that	  need	   to	  administrate	   the	  antiepileptic	  drug	  at	  
home,	  as	  we	  will	  explain.	  
Subjects	  of	  the	  study	  	  
Newborns	   admitted	   at	   the	  NICUs	   (Neonatal	   Intensive	   Care	  Units)	   and	   at	   the	  Hospital	  ward,	  
with	  seizures.	  	  
Inclusion	  and	  Exclusion	  Criteria	  
Inclusion	   Exclusion	  
Preterm	  newborns	  admitted	  at	  the	  NICU	  with	  
a	  convulsive	  episode	  
Newborns	  that	  come	  to	  the	  NICU	  from	  other	  
centres	  where	  they	  have	  already	  received	  a	  
treatment	  
Term	  newborns	  admitted	  at	  the	  NICU	  with	  a	  
convulsive	  episode	  
Newborns	  that	  won’t	  be	  able	  to	  do	  the	  follow	  
up	  because	  of	  bad	  socio-­‐familiar	  support	  
Term	  newborns	  admitted	  at	  the	  Hospital	  ward	  
with	  a	  convulsive	  episode	  
Newborns	  with	  a	  sever/terminal	  prognosis	  	  
Newborns	  treated	  and	  controlled	  with	  just	  1	  
type	  of	  antiepileptic	  drug	  	  
Newborns	  that	  need	  more	  than	  1	  type	  of	  
antiepileptic	  drug	  to	  control	  the	  seizure	  
	  
Sample	  Selection	  
It	  will	  be	  a	  consecutive	  sampling	  as	  the	  seizure	  episodes	  are	  diagnosed	  in	  newborns	  admitted	  
at	  the	  NICU	  and	  hospital	  ward.	  Later	  on	  after	  obtaining	  the	   informed	  consent,	  we	  will	   follow	  
up,	  during	  3	  years,	  the	  neurodevelopment	  of	  these	  newborns.	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Sample	  
Because	   of	   the	   lack	   of	   studies	   about	   the	   proportion	   of	   neurodevelopmental	   alterations	   in	  
newborns	   treated	   with	   phenobarbital,	   we	   take	   onto	   consideration	   that	   the	   proportion	   of	  
newborns	  with	  seizures	  that	  suffer	  from	  neurodevelopment	  problems	  is	  28%.	  Trying	  to	  detect	  
a	   10%	   less	   incidence	   of	   problems	  with	   Levetiracetam,	   accepting	   an	   alpha	   risk	   of	   0’05	   and	   a	  
beta	   risk	   of	   0’20	   in	   a	   one-­‐sided	   test,	   with	   a	   reason	   between	   the	   samples	   equal	   1	   and	   an	  
anticipated	  drop-­‐out	  rate	  of	  5%,	  we	  will	  need	  229	  people	  in	  one	  group	  and	  229	  people	  in	  the	  
other	  group	  to	  achieve	  a	  difference	  statistically	  significant.	  	  
Multicentricity:	   because	   of	   our	   need	   for	   a	   big	   sample	   that	   cannot	   be	   achieved	   only	   for	   our	  
centre,	  we	  propose	  a	  multicenter	   trial.	   To	  establish	  a	   good	   communication	  we	  will	   assign:	   a	  
main	  director	  of	  the	  trial,	  a	  main	  investigator	  in	  each	  centre	  participating	  in	  the	  study	  and	  we	  
will	  guarantee	  the	  quality	  of	  the	  members/staff.	  
• Direction:	  it	  will	  need	  to	  ensure	  that	  the	  chosen	  centres	  are	  appropriate,	  so	  it	  will	  visit	  
them	  and	  it	  will	  meet	  the	  staff.	  The	  criteria	  that	  will	  determine	  if	  the	  centre	  becomes	  a	  
participant	  are:	  	  
o Research	  experience,	  which	  means	  that	  they	  have	  previously	  developed	  other	  
studies	  or	  have	  participated	  in	  them.	  	  
o The	  centre	  has	  a	  Neonatal	  ICU	  
o They	  have	  a	  group	  of	  Neonatologists	  and	  Neuropediatricians	  
o The	  hospital	  has	  to	  assume	  a	  volume	  of	  ≥300.000	  citizens	  to	  ensure	  a	  number	  
of	  deliveries	  big	  enough	  to	  achieve	  our	  sample	  
It	  has	  to	  ensure	  that	  the	  protocol	  is	  followed,	  it	  has	  to	  approve	  any	  modification	  and	  it	  
has	  to	  take	  care	  of	  a	  proper	  distribution	  of	  it.	  It	  will	  establish	  a	  proper	  communication	  
system	   between	   itself	   and	   every	  main	   investigator	   of	   each	   centre,	   and	   has	   to	   be	   in	  
contact	  with	  them	  without	  any	  intermediary	  unless	  it’s	  an	  inevitable	  situation.	  It	  has	  to	  
be	   accessible	   for	   every	   investigator,	   getting	   informed	   of	   any	   incidence.	   It	   will	  
coordinate	  and	  plan	  the	  trial	  and	  ensure	  that	  the	  investigators	  know	  all	  the	  necessary	  
processes.	   Moreover	   it	   has	   to	   have	   previous	   experience	   as	   investigator	   and	   as	   a	  
specialist	  in	  the	  subject,	  and	  minimum	  1	  publication.	  
• Main	  Investigators:	  they	  will	  act	  in	  name	  of	  the	  director	  of	  the	  study	  and	  they	  will	  take	  
the	   responsibility	   to	   achieve	   everything	   it’s	   established	   in	   the	   protocol.	   It	   will	   be	  
required	  experience	  in	  previous	  researches	  as	  participants	  or	  directors,	  and	  minimum	  
1	  publication,	  to	  be	  designated	  as	  main	  investigator.	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• Study	   Staff:	   they	   will	   be	   chosen	   according	   to	   qualifications	   and	   skills	   related	   to	   the	  
tasks	  that	  need	  to	  develop,	  plus	  previous	  experience	  participating	  in	  research.	  	  
It	   will	   be	   a	   unique	   protocol	   and	   every	   centre	   participating	   will	   be	   identified	   with	   a	   main	  
investigator	  and	  it	  will	  have	  the	  description	  of	  their	  tasks.	  Every	  data	  that	  will	  be	  needed	  are	  
going	  to	  be	  described	  in	  the	  protocol	  and	  the	  way	  they	  have	  to	  be	  collected	  too.	  
Variables	  	  
DEPENDANT	  
• Neurodevelopment	  alteration:	  according	  to	  the	  Bayley	  Test	  results,	  specified	  as	  YES	  or	  
NO	  
INDEPENDANT	  
• Drug	  administered:	  Levetiracetam	  or	  Phenobarbital	  
COVARIABLES	  
• Aetiology	  or	  Disease	  that	  cause	  the	  Seizure	  
• Phenobarbital	  dose	  before	  the	  inclusion	  and	  randomization	  
• Duration	  of	  the	  treatment:	  if	  they	  don’t	  need	  treatment	  at	  the	  moment	  of	  the	  hospital	  
discharge	  or	  if	  they	  need	  to	  continue	  with	  the	  treatment	  at	  home,	  and	  the	  duration	  of	  
this.	  This	  situation	  is	  determined	  according	  these	  criteria:	  
o Severe	  Hypoxic-­‐Ischaemic	  Encephalopathy	  or	  Neurological	  Injury	  
o Non	  clinical	  control	  
o Non	  electroencephalographic	  control/normalization	  	  
Data	  Collection	  
It	  will	  be	  a	  neonatologist	  the	  one	  that	  will	  diagnose	  the	  existence	  of	  seizures	  according	  to	  the	  
clinical	  evidence.	  The	  management	  of	  the	  seizure	  will	  be	  done	  following	  these	  steps:	  	  
• Determine	  the	  Glucose	  levels	  to	  diagnose	  a	  seizure	  that	  doesn’t	  need	  an	  antiepileptic	  
drug.	  	  
• For	   ethical	   reasons	   and	   viability	   of	   the	   study,	   and	   for	   the	   need	   of	   a	   consecutive	  
sampling	  to	  achieve	  our	  sample,	  newborns	  that	  suffer	  seizures	  will	  receive	  treatment	  
with	  Phenobarbital	  to	  stop	  the	  crisis	  while	  their	  parents	  receive	  the	  Informed	  Consent	  
and	  decide	  if	  their	  child	  is	  included	  in	  the	  study.	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• Newborns	  whose	   parents	   accept	   to	   participate	   in	   the	   study	  will	   start	   the	   treatment	  
with	  Levetiracetam	  or	  will	  continue	  with	  Phenobarbital,	  randomly.	  The	  dosage	  will	  be:	  
o Phenobarbital:	   loading	   dose	   of	   20mg/kg	   in	   10-­‐15	  minutes	   (intravenous).	  We	  
will	  administer	  additional	  doses	  of	  5mg/kg	  until	  we	  stop	  the	  crisis	   (maximum	  
dose	   of	   40mg/kg).	   We	   will	   maintain	   a	   dose	   of	   5mg/kg/24h	   divided	   in	   two	  
doses	   a	   day	   achieving	   blood	   levels	   between	   ≤40μg/ml	   -­‐	   >10μg/ml.	   We	   will	  
follow	   this	   pattern	   until	   the	   newborn	   is	   included	   in	   the	   trial	   and	   after	   that,	  
randomly,	   it	   will	   continue	   with	   this	   treatment	   or	   it	   will	   change	   to	  
Levetiracetam.	  	  
o Levetiracetam:	   initial	   dose	   of	   10mg/kg/12h	   (intravenous)	   that	   results	   in	  
20mg/kg/day.	  In	  three	  days	  we	  will	  increase	  the	  doses	  (10mg/kg/12h	  per	  day,	  
which	   results	   20mg/kg/day)	   until	   we	   reach	   30mg/kg/12h,	   a	   total	   amount	   of	  
60mg/kg/day.	  	  
It	  will	  be	  intravenous	  until	  the	  newborn	  is	  able	  to	  take	  the	  oral	  solution.	  	  
• In	   case	   of	   treatment	   failure	   the	   procedure	   will	   be:	   blood	   sample	   and	   drug	   levels	  
determination.	  After	  that	  we	  will	  receive	  the	  results	  from	  the	  laboratory	  and	  in	  case	  of	  
optimum	  levels	  we	  will	  consider	  that	  the	  newborn	  doesn’t	  respond	  to	  only	  1	  drug	  and	  
for	  security	  reasons	   it	  will	  be	  excluded	  from	  the	  study	  and	  it	  will	   initiate	  a	  treatment	  
with	  Phenytoin	  (second	  line	  treatment).	  On	  the	  contrary,	  non	  optimum	  levels,	  we	  will	  
administer	  a	  new	  dose	  to	  achieve	  the	  therapeutic	  levels.	  	  
Thereafter	  we	  will	  perform	  the	  following	  procedures:	  
1. Before	  the	  hospital	  discharge:	  
a. Drug	  used	  
b. EEG	  register	  
c. Neurological	  evaluation	  
These	  data	  will	  determine	  the	  need,	  as	  we	  have	  already	  explained,	  to	  continue	  or	  not	  
the	  antiepileptic	  treatment	  at	  home.	  	  
	  
2. After	  the	  hospital	  release:	  	  
If	  we	  need	  to	  continue	  with	  the	  treatment	  at	  home	  (which	  will	  be	  established	  by	  the	  criteria	  
already	  mentioned)	  the	  parents	  will	  collect	  the	  medication,	  while	  the	  treatment	  is	  needed,	  at	  
the	  hospital	  on	  the	  days	  they	  visit	  the	  neuropediatrician	  for	  the	  routine	  evaluation.	  They	  won’t	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know	  the	  drug	  they	  are	  administering,	   the	  drug	  will	  be	  codified	  to	  assure	  the	  blind.	  This	  will	  
continue	  until	  the	  normalization	  of	  the	  EEG,	  which	  will	  determine	  the	  stop	  of	  the	  treatment.	  	  
During	  the	  routine	  evaluation	   in	   the	  neuropediatrician	   (every	  3	  months	  during	  the	   first	  year,	  
every	   6	  months	   during	   the	   second	   year)	  we	  will	   collect	   data	   about	   de	  motor	   development,	  
language,	  cognition	  and	  socio-­‐emotional	  behaviour	  according	  to	  the	  Haizea-­‐Llevant	  Scale.	  This	  
data	  will	  be	  registered	  as	  achieved	  or	  non-­‐achieved.	  At	  the	  age	  of	  three	  a	  neuropsychologist	  
will	  perform	  the	  Bayley	  test,	  which	   is	  designed	  to	   identify	  the	  abilities	  that	  the	  children	  have	  
using	   activities	   that	   simulate	   games.	   The	  neuropsychologists	  won’t	   know	   the	  drug	   used	   and	  
will	  evaluate:	  
-­‐ Cognition	  
-­‐ Language:	  expressed,	  received	  
-­‐ Gross	  and	  fine	  motor	  skills	  
-­‐ Socio-­‐emotional	  	  
The	   statistical	   study	   used	   for	   the	  main	   objective	  will	   be	   a	   logistic	   regression,	   presenting	  OR	  
adjusted	  for	  the	  covariables	  already	  mentioned,	  and	  a	  multinomial	  regression	  will	  be	  used	  for	  
the	  secondary	  objective,	  adjusted	  for	  the	  covariables	  too.	  	  
Staff	  
• Statistician:	  it	  will	  use	  the	  data	  for	  the	  statistical	  analysis.	  	  
• Neuropsychologists:	   in	   charge	   of	   the	   evaluation	   of	   the	   neurodevelopment	   using	   the	  
Bayley	  Test.	  	  
• Neuropediatricians:	   in	   charge	   of	   the	   routine	   evaluations	   of	   these	   children,	   and	   the	  
ones	  in	  charge	  to	  stop	  the	  treatment	  if	  they	  had	  had	  to	  continue	  it	  at	  home.	  
• Neonatologists:	   in	   charge	   to	   diagnose	   the	   neonatal	   seizures	   and	   authorize	   the	  
treatment	  and	  determine	  the	  success	  of	  the	  treatment.	  	  
• Nurses:	  in	  charge	  to	  administrate	  the	  drug	  and	  to	  collect	  the	  data.	  
• Laboratory	  Staff:	  in	  charge	  to	  check	  the	  drug	  levels	  in	  the	  blood	  samples	  if	  we	  need	  a	  
new	  dose	  for	  the	  treatment.	  	  
• Main	  Investigators:	  in	  charge	  to	  guarantee	  the	  quality	  level	  of	  the	  centre.	  They	  will	  be	  
in	  touch	  with	  the	  Director	  of	  the	  Project.	  	  
• Pharmacy:	   in	   charge	   to	  prepare	   the	  drug	   for	   the	   treatment	  at	  home	  and	  ensure	   the	  
blind	  for	  the	  parents	  with	  a	  codification.	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Limitations	  
• The	  aetiology	  or	  disease	  that	  causes	  the	  seizures	  may	  disturb	  our	  results.	  The	  way	  we	  
will	  solve	  it	  is	  with	  the	  randomization,	  equivalently	  distributing	  the	  samples.	  	  
• The	  sample	  we	  need	  is	  quite	  large,	  so	  this	  can	  difficult	  the	  reproduction	  of	  this	  study.	  
We	  will	  solve	  this	  with	  the	  multicentricity,	  which	  will	  increase	  the	  population	  available.	  
• For	   ethical	   reasons	   and	   for	   the	   viability	   of	   the	   project	   we	   will	   need	   to	   administer	  
Phenobarbital	   to	   every	   newborn	   before	   starting	   the	   study,	   so	   our	   results	   will	   be	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6.	  ETHICAL	  ASPECTS	  	  
This	   clinical	   trial	   follows	   the	   declaration	   of	   Helsinki	   involving	   ethical	   principles	   for	   Medical	  
Research	  involving	  Human	  subjects	  (last	  actualization	  October	  2013).	  
It	  will	  be	  send	  to	  the	  ethic	  committees	  of	  all	  the	  centres	  participating	  in	  our	  study	  and	  has	  to	  
be	  approved	  in	  each	  one	  of	  them	  to	  be	  performed.	  	  
It	  will	  be	  performed	  according	  the	  Spanish	  Laws	  related	  to	  clinical	  trials:	  	  
“Ley	  29/2006	  de	  26	  de	  julio,	  de	  garantías	  y	  uso	  racional	  de	  los	  medicamentos	  y	  productos	  
sanitarios:	  
•	  RD	  223/2004	  de	  6	  de	  febrero:	  ensayos	  clínicos	  con	  medicamentos	  	  
•	   RD	   1591/2009	   de	   16	   de	   octubre	   y	   1616/2009	   de	   26	   de	   octubre:	   investigación	   con	  
productos	  sanitarios”	  
And	  it	  will	  be	  registered	  in	  the	  EUDRA-­‐CT.	  
	  
Every	   subject	   participating	   in	   this	   clinical	   trial	   will	   be	   properly	   informed	   and	   it	   will	   sign	   an	  
Informed	  Consent	  (Appendix	  1	  and	  Appendix	  2).	  The	  data	  collected	  for	  the	  trial	  will	  be	  always	  
treated	  and	  used	  anonymously	  preserving	  the	  confidentiality	  of	  the	  patients.	  	  
This	  clinical	  trial	  has	  an	  insurance	  to	  take	  the	  responsibility	  towards	  its	  members	  if	  any	  adverse	  
event	  is	  suffered	  because	  of	  our	  study/intervention.	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7.	  CHRONOGRAM	  	  	  
The	   duration	   of	   this	   clinical	   trial	   is	   5	   years	   and	  will	   be	   organized	   according	   to	   the	   following	  
phases.	  	  
1. Coordination	   of	   the	   centres	   and	  members	   of	   the	   study:	   2	  months.	   Selection	   of	   the	  
centres	  that	  will	  participate	  in	  the	  study,	  checking	  the	  quality	  of	  the	  staff	  according	  to	  
the	  needs	  for	  the	  trial.	  In	  addition,	  it	  will	  be	  a	  meeting	  to	  explain	  the	  communication	  
system,	  to	   introduce	  the	  chiefs	  of	   the	   investigation,	   to	  solve	  all	   the	  questions	  and	  to	  
check	  that	  the	  protocol	  has	  been	  understood	  and	  will	  be	  followed	  according	  to	  what’s	  
been	  established.	  	  
2. Sample	   Collection	   and	   Treatment	   of	   the	   Convulsive	   Event:	   1	   year.	   Collecting	   the	  
sample	  in	  order	  of	  appearance	  and	  distributing	  randomly	  the	  drugs	  of	  the	  study.	  Treat	  
the	  newborns	  and	  collect	  the	  variables	  needed.	  	  
3. Meeting	  nº1:	  1	  month.	  After	  the	  end	  of	  the	  sample	  collection	   it	  will	  be	  established	  a	  
meeting	  to	  check	  the	  quality	  of	  the	  data	  collected	  in	  each	  centre	  and	  to	  check	  that	  the	  
rules	  have	  been	  followed.	  	  
4. Follow	  Newborns:	   2	   years	   since	   birth.	   Every	   3	  months	   during	   the	   first	   year,	   every	   6	  
months	   during	   the	   second	   year,	   as	   it’s	   established	   for	   any	   newborn	   suffering	   from	  
neonatal	  seizures.	  It	  will	  be	  checked	  the	  evolution	  and	  the	  neurodevelopmental	  status	  
according	  to	  the	  standard	  methods	  (Haizea-­‐Levant).	  
5. Meeting	   nº2:	   1	   month,	   between	   year	   1	   and	   2.	   To	   check	   that	   everything	   it’s	   being	  
performed	  as	  it’s	  established.	  
6. Bayley	  Test:	  1	  year.	  At	  the	  age	  of	  3	  years	  these	  toddlers	  will	  undergo	  to	  the	  Bayley	  Test	  
by	   the	  Neuropsychologists,	   to	   check	   their	  neurodevelopmental	   status	  and	  problems.	  
We	  will	  need	  a	  year	  according	  to	  the	  fact	  that	  we	  would	  have	  been	  collecting	  babies	  
for	  a	  year	  and	  they	  will	  be	  3	  years	  old	  at	  different	  times.	  	  
7. Meeting	   nº3:	   1	   month.	   To	   check	   that	   the	   data	   collection	   has	   been	   performed	  
according	  to	  the	  protocol.	  	  
8. Results:	   1	   year.	   The	   statistician’s	   analysis	  with	   the	   data	   collected	   and	   results.	   Plus	   a	  
meeting	  of	  the	  members	  of	  the	  trial	  to	  evaluate	  the	  conclusions.	  	  
9. Publication:	  10	  months.	  Write	  and	  edit	  the	  results	  to	  publish	  them.	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Publications	   	   	   	  
Seminars	  in	  Fetal	  and	  Neonatal	  
Medicine	  	  
3000	  €	  	   	   3000	  €	  
TOTAL	  	   	   195.418	  €	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This	  budget	  has	  been	  done	  according	  to	  the	  fact	  that	  this	  is	  a	  multicentric	  clinical	  trial.	  As	  we	  
consider	  including	  4	  centres	  to	  this	  project,	  here	  we	  provide	  the	  explanation	  for	  the	  costs:	  
• Staff:	  we	  will	  need	  neuropsychologists	  that,	  as	  experts,	  will	  set	  the	  Bayley	  Tests	  to	  the	  
toddlers	  in	  order	  to	  establish	  their	  neurodevelopmental	  status.	  Each	  one	  of	  them	  will	  
be	  placed	   in	   the	  different	  member	  centres.	  Moreover	  we’ll	  need	   two	  statisticians	   to	  
analyze	  the	  data	  collected.	  Because	  of	  the	  fact	  that	  Levetiracetam	  is	  not	  the	  first	   line	  
treatment	  and	  we	  will	  use	   it	   as	  a	  main	   treatment	   for	  229	  patients	   this	  will	   cause	  an	  
extra	  expenditure	  that	  has	  to	  be	  included	  as	  an	  important	  part	  of	  the	  budget.	  	  
• Material:	  taking	  onto	  consideration	  that	  we	  won’t	  be	  able	  to	  perform	  at	  certain	  hours	  
of	  the	  day	  an	  EEG,	  we	  have	  considered	  buying	  an	  Amplitude	  Integrated	  EEG,	  which	  can	  
be	   used	   by	   any	   neonatologist	   (not	   necessary	   a	   neurophysiologist)	   and	   can	   diagnose	  
and	  show	  any	  pathologic	  pattern.	  Moreover,	  for	  each	  centre	  we’ll	  need	  a	  Bayley	  Test	  
Set1,	  for	  each	  Neuropsychologist	  to	  work	  with.	  	  
• Meetings:	  we	  include	  in	  the	  budget	  two	  major	  meetings	  where	  we	  plan	  to	  explain	  our	  
results,	  a	  national	  one	  and	  an	  international	  one.	  Taking	  onto	  consideration	  that	  it’s	  2	  
people	   per	   meeting,	   the	   flights	   to	   the	   national	   one	   cost	   approximately	   130€	   and	  
international	  (Europe)	  cost	  150€,	  which	  in	  total	  it’s	  560€.	  For	  the	  accommodation	  we	  
propose	  a	  4	  star	  hotel	  for	  4	  nights	  for	  both	  meetings	  and	  same	  number	  of	  participants	  
(2	  per	  meeting),	  which	  will	  cost	  maximum	  170€	  for	  each	  Congress/person.	  	  
• Publications:	   we	  want	   to	   publish	   in	   two	   journals	   each	   one	   chosen	   according	   to	   the	  
impact	   of	   our	   clinical	   trial,	   one	   involving	   the	   neuropaediatricians	   and	   another	   one	  
involving	  neonatologists.	  One	  of	   them	  charges	  no	   costs	   to	   the	  publication	   so	   its	   not	  
added	  in	  the	  budget;	  the	  costs	  of	  the	  other	  one	  (Elsevier	  Editorial)	  includes	  the	  fee	  to	  






	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Bayley	  Test	  is	  not	  included	  in	  this	  document	  because	  of	  its	  magnitude.	  It’s	  an	  integrated	  kit	  with	  games	  and	  other	  
materials	  that	  cannot	  be	  added.	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10.	  IMPACT	  OF	  THE	  PROJECT	  	  
Despite	   the	   number	   of	   studies	   that	   have	   proved	   that	   phenobarbital	   causes	  
neurodevelopmental	   problems	   in	   newborns	   treated	   for	   neonatal	   seizures,	   this	   drug	   has	   still	  
been	  used	  among	  children	  as	  the	  main	  treatment	  because	  of	  his	  efficacy,	  not	  always	  absolute,	  
in	  arresting	  these	  events.	  However	  the	  emergence	  of	  new	  drugs	  that	  have	  proved	  nowadays	  
that	  have	  no	  secondary	  effects,	  show	  up	  new	  theories	  and	  assumptions	  that	  may	  change	  the	  
way	  these	  newborns	  are	  treated,	  decreasing	  the	  dangerous	  effects	  on	  his	  neurodevelopment.	  
And	   among	   these	   new	   generation	   drugs,	   Levetiracetam	   has	   become	   the	   one	   around	  whom	  
every	  studies	  are	  focused	  on.	  	  
At	  the	  present	  time	  there	  is	  only	  one	  retrospective	  study	  still	  on	  review	  from	  November	  2013	  
that	  compares	  the	  effect	  between	  Phenobarbital	  and	  Levetiracetam	  on	  the	  neurodevelopment	  
of	   these	   children.	   However	   there	   are	   lots	   of	   other	   studies	   (in	   rats/mice)	   proving	   that	  
Phenobarbital	   causes	   damage	   or	   injury	   in	   their	   CNS.	   All	   of	   them	   insist	   on	   the	   need	   of	  
prospective	  studies	  that	  compare	  these	  two	  drugs	  and	  prove	  the	  association	  clearly	  in	  order	  to	  
change	  the	  way	  we	  manage	  neonatal	  seizures,	  to	  change	  and	  decrease	  the	  morbidity	  caused	  
by	  the	  iatrogenic	  effects	  of	  the	  drugs	  we	  use.	  	  
Referring	   to	   the	   incidence	   of	   these	   episodes:	   1-­‐2/1000	  on	   term	  newborns	   and	   30-­‐130/1000	  
premature	   newborns,	   changing	   the	   pattern	   of	   treatment	   and	   diminishing	   the	   long-­‐term	  
problems	   will	   entail	   a	   minor	   investment	   by	   the	   Public	   Health	   Services.	   In	   the	   long	   run	   this	  
newborns	  won’t	  need	  so	  many	  support	  from	  neuropsychologists	  or	  other	  health	  professionals	  
because	  we	  would	  have	  decreased	   the	   level	  of	  dangerous	  effects	   that	   the	  drugs	   themselves	  
can	  induce	  over	  the	  CNS	  of	  these	  children.	  	  
To	  sum	  up	  and	  to	  conclude:	  we	  will	  decrease	  the	  morbidity	  caused	  by	  the	  drug	  and	  therefore	  
the	   health	   expenditure	   and	   family	   disruption	   arising	   from	   this.	   This	   results	   as	   a	   beneficial	  
effect	   over	   the	   families,	   decreasing	   the	   stress	   and	   emotional	   suffering	   that	   comes	   from	   the	  
neurological	   disabilities	   of	   a	   child,	   and	   over	   the	   National	   Health	   System,	   decreasing	   the	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APPENDIX	  1.	  FULL	  D’INFORMACIÓ	  PEL	  PACIENT	  
Aquest	  document	  està	  destinat	  als	  pares	  dels	  nadons	   ingressats	  en	  el	  nostre	  centre	   i	  als	  que	  
se’ls	  convida	  a	  participar	  en	  l’estudi	  sobre	  els	  efectes	  sobre	  el	  neurodesenvolupament	  per	  l’ús	  
de	  Fenobarbital	  versus	  Levetiracetam	  en	  el	  maneig	  de	  les	  convulsions	  neonatals.	  	  
Es	  divideix	  en:	  	  
• Informació	  pel	  participant	  
• Formulari	  de	  Consentiment	  Informat	  
Les	   convulsions	   neonatals	   són	   una	   manifestació	   freqüent	   de	   malfunció	   del	   sistema	   nerviós	  
central	   en	   el	   neonat,	   i	   són	   un	   factor	   de	   risc	   per	   a	  mort	   o	   discapacitat	   neuronal	   conferint	   al	  
infant	  un	  pobre	  desenvolupament	  neurologic,	  fet	  que	  inclou	  alteracions	  de	  la	  cognició,	  social	  i	  
emocional,	  de	  llenguatge	  i	  motores.	  	  
Les	   convulsions	   resulten	   d’una	   descàrrega	   excessiva	   i	   sincronica	   d’un	   grup	   de	   neurones	   del	  
sistema	   nerviós,	   manifestant-­‐se	   amb	   episodis	   de	   moviments	   anormals	   o	   amb	   senyals	  
patológiques	  en	  electroencefalogrames.	  	  
Actualment	  el	  seu	  maneig	  es	  fa	  amb	  Fenobarbital,	  però	  recent	  estudis	  han	  suggerit	  que	  aquest	  
farmac	  pot	  influïr	  en	  el	  desenvolupament	  neurologic	  de	  l’infant,	  portant	  aquest	  fet	  a	  generar	  
nous	  estudis	  en	  busca	  de	  nous	  fàrmacs.	  Els	  resultats	  ens	  han	  indicat	  que	  el	  Levetiracetam,	  un	  
antiepilèptic	  de	  nova	  generació	  referit	  com	  a	  eficaç	  pel	  maneig	  de	   les	  convulsions	  neonatals,	  
podria	  ser	  una	  bona	  alternativa	  per	  aquests	  infants,	  disminuïnt	  els	  possibles	  efectes	  secundaris	  
del	  primer.	  	  
Amb	   aquest	   estudi	   volem	   determinar	   als	   3	   anys,	   quin	   es	   l’estat	   del	   desenvolupament	   dels	  
infants	   tractats	   amb	   Fenobarbital	   o	   Levetriacetam	   per	   a	   poder	   presentar	   en	   un	   futur	   una	  
alternativa	  a	  la	  teràpia	  actual.	  	  
Es	   tracta	   d’un	   assaig	   clínic	   que	   consisteix	   en	   l’administració	   aleatoria	   d’un	   dels	   dos	   fàrmacs	  
(Fenobarbital	   o	   Levetiracetam)	   pel	   maneig	   incial	   de	   la	   convulsió.	   L’aleatorització	   assegura	  
l’assignació	   dels	   participants	   a	   un	   dels	   dos	   grups	   de	   l’estudi	   tinguent	   aquests	   la	   mateixa	  
probabilitat	  de	  ser	  assignats	  a	  un	  grup	  o	  un	  altre.	  	  
Posteriorment	  l’infant	  serà	  seguit	  pel	  servei	  de	  neuropediatria	  en	  els	  terminis	  habituals	  per	  a	  
qualsevol	  nadó	  que	  hagi	  patit	  un	  succés	  convulsiu	  en	  el	  període	  neontal.	  Finalment	  als	  3	  anys	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serà	  sotmés	  al	  test	  neuropsicológic	  de	  Bayley	  pels	  nostres	  especialistes,	  per	  determinar	  l’estat	  
del	  desenvolupament	  neurológic	  i	  identificar-­‐ne	  o	  no	  algun	  dèficit.	  	  
En	   cas	   que	  durant	   el	   quadre	   convulsiu	   es	   necessiti	  medicació	   de	   rescat	   pel	  maneig,	   el	   nadó	  
serà	  sotmés	  a	  un	  anàlisi	  de	  sang	  que	  ens	  determinarà	  nivells	  de	  fàrmac	  en	  circulació	  i	  respecte	  
a	  aquests	  rebrà	  les	  dosis	  necessaries	  i	  establertes	  de	  tractament	  seguint	  una	  de	  les	  dues	  vies	  
següents:	  	  
• Proseguirà	  amb	  el	  farmac	  de	  l’estudi	  si	  els	  nivells	  d’aquests	  encara	  no	  eren	  els	  óptims.	  
• Rebrà	   el	   fàrmac	   de	   segona	   línea	   (Fenitoïna)	   en	   cas	   que	   els	   nivells	   ja	   fossin	   óptims	  
essent	  així	  exclós	  de	  l’estudi,	  prioritzant-­‐ne	  la	  seva	  salut	  a	  la	  investigació.	  	  
Com	   s’esmenta,	   el	   fàrmac	   estandard	   per	   al	   maneig	   de	   les	   convulsions	   podria	   influïr	  
parcialment	   (a	   part	   de	   la	   patologia	   base)	   en	   el	   desenvolupament	   neurológic	   de	   l’infant;	   no	  
obstant	   la	   teràpia	   alternativa	   es	   desconeix	   a	   llarg	   plaç	   algun	   efecte	   secundari,	   i	   per	   tant	   no	  
podria	  descartar-­‐se’n.	  En	  ambdós	  casos	  el	  seguiment	  exhaustiu	  propiciarà	  el	  maneig	  adecuat	  
de	  l’infant	  en	  cas	  que	  fos	  necessari.	  	  
Els	  convidem	  doncs	  a	  participar	  en	  el	  nostre	  estudi	  sobre	  el	  Fenobarbital	  i	  el	  Levetiracetam.	  La	  
seva	   participació	   pot	   determinar	   un	   benefici	   directa	   o	   indirectament	   	   per	   a	   futures	  
generacions,	   donant	   resposta	   a	   la	   nostra	   pregunta	   i	   poguent	   alterar	   el	  maneig	   futur	   de	   les	  
convulsions	  neonatals.	  	  
La	   participació	   en	   aquest	   estudi	   es	   totalment	   voluntaria.	   La	   decisió	   de	   no	   incloure’s	   no	  
canviarà	  el	  seguiment	  estàndard	  del	  nostre	  centre	  i	  rebrà	  el	  tractament	  estàndar	  per	  al	  maneig	  
de	  l’event	  convulsiu.	  Podrà	  abandonar	  l’estudi	  si	  ho	  considera	  necessari,	  és	  la	  seva	  elecció	  i	  els	  
seus	  drets	  seran	  respectats.	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APPENDIX	  2.	  FORMULARI	  DE	  CONSENTIMENT	  INFORMAT	  
Jo	   _______________________	   i	   _________________	   com	   a	   mare/pare/tutor	   legal,	   de	  
_______________	   autoritzo	   voluntariament	   la	   participació	   del	   meu	   fill/a	   	   en	   la	   investigació	  
sobre	   l’ús	  de	  Fenobarbital	  o	   Levetiracetam	  pel	  maneig	  de	   les	  Convulsions	  Neonatals	   i	   el	   seu	  
efecte	   sobre	   el	   Neurodesenvolupament,	   i	   entenc	   el	   dret	   de	   retirar-­‐lo/la	   de	   l’estudi	   en	  
qualsevol	  moment	  sense	  que	  m’afecti	  de	  cap	  manera	  el	  meu	  tracte	  medic.	  
Així	  mateix	  expresso	  que	  he	  llegit	  o	  m’ha	  estat	  llegida	  la	  infromació	  sobre	  l’estudi	  per	  part	  de	  	  
___________________	   ,	   tinguent	   l’oportunitat	   de	   preguntar	   i	   rebre	   respostes	   satisfactories	  
sobre	  l’estudi.	  	  
Finalment	   se’ns	   ha	   informat	   que	   en	   cas	   necessari,	   per	   la	   seguretat	   del	   nostre	   fill,	   els	  
professionals	  aplicaran	  les	  mesures	  necessaries	  pel	  maneig	  de	  les	  convulsions	  i	  ens	  informaran	  












_____	  de	  ______________________	  del	  20__	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APPENDIX	  3.	  HAIZEA-­‐LLEVANT	  SCALE	  
